文献速递胸部肿瘤

新冠mRNA疫苗接种改善接受放疗的非小细胞肺癌生存

SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With Radiotherapy.
PubMed 文献 · J Thorac Oncol · 2026-06-01

本研究基于413例大流行期间接受SABR的T1-3N0M0非小细胞肺癌真实世界患者,其中144例在SABR前后3个月内接种新冠mRNA疫苗。时间依赖分析显示接种与无复发生存改善相关(HR=0.69,95%CI 0.49-0.98,p=0.039),倾向性评分匹配后无复发生存(HR=0.61,95%CI 0.40-0.91,p=0.016)和总生存(HR=0.57,95%CI 0.34-0.94,p=0.029)均改善。

要点

  • 围SABR期接种新冠mRNA疫苗与NSCLC患者无复发生存改善独立相关。
  • 倾向性评分匹配后接种组总生存亦显著改善(HR=0.57,p=0.029)。
  • 结果支持进一步研究mRNA疫苗与SABR抗肿瘤免疫的交互作用。

核心结论

  • 围SABR期接种SARS-CoV-2 mRNA疫苗与T1-3N0M0 NSCLC患者无复发生存改善相关,匹配后总生存亦改善。

研究设计与样本

  • 真实世界回顾性队列研究,纳入大流行期间接受SABR的413例T1-3N0M0 NSCLC患者,其中144例在SABR前后3个月内接种疫苗。

主要发现

  • 时间依赖分析中接种与无复发生存改善相关(HR=0.69,95%CI 0.49-0.98,p=0.039),总生存呈改善趋势(HR=0.66,95%CI 0.42-1.03,p=0.069)。
  • 倾向性评分匹配时间依赖分析中接种与无复发生存改善相关(HR=0.61,95%CI 0.40-0.91,p=0.016)。
  • 倾向性评分匹配时间依赖分析中接种与总生存改善相关(HR=0.57,95%CI 0.34-0.94,p=0.029)。
  • 多变量校正后结果方向一致。

临床怎么用

  • 对于接受SABR的早期NSCLC患者,围治疗期接种新冠mRNA疫苗可能带来生存获益,但需前瞻性研究验证。

局限性

  • 真实世界回顾性设计可能存在残余混杂,疫苗接种组与未接种组基线特征差异需考虑。
  • 总生存在时间依赖分析中仅呈趋势,匹配后样本量减少可能影响统计效能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stereotactic ablative radiotherapy (SABR) is standard for early stage NSCLC, but strategies to enhance its systemic antitumor immune effects remain limited. Preclinical data suggest that severe acute respiratory syndrome coronavirus 2 mRNA vaccines enhance innate immunity and antigen presentation, raising the possibility that vaccination could augment radiotherapy-induced immune priming. We evaluated the clinical impact of peri-SABR vaccination (defined as within 3 mo before or after SABR) in 413 real-world patients with T1 to 3N0M0 NSCLC who were treated during the pandemic era, including 144 patients who received vaccination within this window. In time-varying analyses, vaccination was associated with improved recurrence-free survival (hazard ratio [HR] = 0.69, 95% confidence interval [CI]: 0.49-0.98, p = 0.039) and a trend toward improved overall survival (HR = 0.66, 95% CI: 0.42-1.03, p = 0.069). In propensity score-matched time-dependent analyses, vaccination remained associated with improved recurrence-free survival (HR = 0.61, 95% CI: 0.40-0.91, p = 0.016) and overall survival (HR = 0.57, 95% CI: 0.34-0.94, p = 0.029), with directionally consistent findings observed after multivariable adjustment. These findings support further investigation into potential interactions between severe acute respiratory syndrome coronavirus 2 mRNA vaccination and SABR-induced antitumor immunity.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Xu X, Saad MB, Grippin A, et al. SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated With Radiotherapy. J Thorac Oncol. 2026. PMID: 42229634. doi:10.1016/j.jtho.2026.103956

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。